SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 62.04 |
Enterprise Value ($M) | 58.91 |
Book Value ($M) | -18.55 |
Book Value / Share | -7.62 |
Price / Book | -3.34 |
NCAV ($M) | -18.91 |
NCAV / Share | -7.77 |
Price / NCAV | -3.28 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | n/a |
Return on Assets (ROA) | -0.70 |
Return on Equity (ROE) | -49.63 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 1.00 |
Current Ratio | 1.00 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 10.66 |
Assets | 11.02 |
Liabilities | 29.57 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | -25.50 |
Net Income | -20.25 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -19.08 |
Cash from Investing | 4.40 |
Cash from Financing | 12.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13D/A | MacAndrews & Forbes Inc. | 50.30 | -97.50 | |
13D | Baker Bros. Advisors Lp | 4.99 | ||
13D | Samsara BioCapital, L.P. | 10.40 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
133 | 1,561 | 8.52 | |
516 | 4,082 | 12.64 | |
1,090 | 1,563 | 69.74 | |
547 | 842 | 64.96 | |
(click for more detail) |
Similar Companies | |
---|---|
VRPX – Virpax Pharmaceuticals, Inc. | VSTM – Verastem, Inc. |
VTGN – Vistagen Therapeutics, Inc. | VXRT – Vaxart, Inc. |
VYNE – VYNE Therapeutics Inc. |
Financial data and stock pages provided by
Fintel.io